Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024. REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

Accolade

CRISPR Therapeutics

Intellia Therapeutics

Invitae

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

23andMe

AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability.

Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe

Shares of Recursion Pharmaceuticals Inc. RXRX, +3.30% jumped more than 4% premarket on Thursday after chip giant Nvidia Corp. NVDA, +3.17% on Wednesday posted blowout quarterly results. Recursion last month announced a $50 million investment from Nvidia, structured as a private investment in public equity, and plans to accelerate drug discovery using artificial intelligence.

Recursion Pharmaceuticals stock gets boost after Nvidia results

Caribou Biosciences

Biotechs tend to be very risky investments. Picking businesses with good management and plenty of cash can reduce risk.

3 Clever Tricks to Find Winning Biotech Stocks

Apellis Pharma

Deciphera Pharmaceuticals

Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.

Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now

Biotech will benefit immensely from new artificial intelligence tools. Companies are also starting to create some enormously complex new therapies.

3 Green Flags for Biotech Stocks in 2023 and Beyond

Recursion's pipeline is chasing a handful of relatively small opportunities. Its collaboration with Nvidia will take some time to pay off, assuming it does.

3 Things About Recursion Pharmaceuticals That Smart Investors Know

AbCellera Biologics

Lantern Pharma

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI stocks to invest in. At the moment, new drug development has a ridiculous fail rate of 90%, according to the National Institutes of Health.

3 AI Stocks You'll Regret Not Buying Soon

Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world's largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica's MatchMaker technology. Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world's largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica's MatchMaker technology.

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

GE HealthCare Technologies Inc

Recursion is a clinical-stage biotech that is benefiting from big-time partnerships. GE Healthcare has AI algorithms built into the software with its imaging and diagnostic systems.

2 Healthcare AI Stocks That Could Go Parabolic

Valence Labs is Recursion's new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships. Valence Labs is Recursion's new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Schrodinger 

Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.

Biotech Stocks Join AI-Fueled Rally

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.

3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other

Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

The artificial intelligence (AI) trade has been blistering higher, but Wednesday featured an interesting surge. That's as shares of Recursion Pharmaceuticals (NASDAQ: RXRX ) are exploding higher on the day.

Did Nvidia Just Trigger a Short Squeeze in RXRX Stock?

Schrödinger and Recursion Pharmaceuticals use AI to improve drug development. Neither one has proven its business model to be viable yet.

Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals

NVIDIA just announced an investment in Recursion Pharmaceuticals. Recursion still may not have a medicine out the door for a while.

NVIDIA Just Invested $50 Million in This Biotech -- Should You Buy It?

Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used to construct and navigate vast datasets, enabling the identification of patterns in the data that would be impossible for humans to detect. Despite significant revenue growth, Recursion's ability to generate revenue is still very hard to predict, and therefore the dilution risk looms large for shareholders.

Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint

Blueprint Medicines

ExScientia Ltd

The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE: MDT ) led the way, partnering with tech giants such as Nvidia (NASDAQ: NVDA ), to develop AI-powered solutions to medical problems.

3 Biotech Stocks Using AI to Change Healthcare Forever

NVIDIA

Nvidia is investing $50 million in Recursion Pharmaceuticals. The two companies are also working together to use AI to speed up drug discovery.

Why Recursion Pharmaceuticals Stock Is Skyrocketing This Week (Hint: Thanks, Nvidia)

Recursion Pharmaceuticals (NASDAQ: RXRX ) stock is the talk of Wall Street lately. Indeed, RXRX soared more than 120% Wednesday after Nvidia (NASDAQ: NVDA ) announced it would invest $50 million into the biotech firm to use artificial intelligence (AI) for drug discovery.

Did Nvidia Make Recursion Pharmaceuticals (RXRX) Stock the Next AI Play?

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

Tech giant NVIDIA Corporation (NASDAQ:NVDA) has dedicated US$50mln to a multi-year collaboration with US-listed biotech company Recursion Pharmaceuticals to develop AI-based software for improving patient treatments.  Recursion also announced plans to accelerate the development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimise and distribute to biotechnology companies using NVIDIA cloud services.

Nvidia and Recursion Pharmaceuticals team up on AI-based biotech collaboration

News for Recursion Pharmaceuticals Stock (RXRX)